Skip to main content
Log in

Short-term treatment of gastroesophageal reflux disease

A systematic review and meta-analysis of the effect of acid-suppressant drugs in empirical treatment and in endoscopy-negative patients

  • Review
  • Published:
Journal of General Internal Medicine Aims and scope Submit manuscript

Abstract

OBJECTIVE: To investigate the efficacy of acid suppressant drugs in the empirical treatment of gastroesophageal reflux disease (GERD) and in the treatment of endoscopy-negative reflux disease (ENRD).

DESIGN: MEDLINE, EMBASE, and the Cochrane Controlled Trials Register were searched. Bibliographies were reviewed.

SETTING: Studies were eligible that compared the short-term use of proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) with each other or with placebo in adults with GERD who were enrolled irrespective of endoscopic findings (empirical cases) or in whom endoscopy showed no signs of esophagitis (endoscopy-negative cases).

MEASUREMENTS: Of 1,408 studies, only 13 could be included for meta-analysis. Data on 3,433 patients empirically treated for GERD and 2,520 patients treated for ENRD were extracted. The primary endpoint was relief of heartburn.

MAIN RESULTS: In the empirical treatment of GERD, the summary relative risk (sRR) for symptom relief from H2RAs versus placebo was 0.77 (95% confidence interval [95% CI], 0.60 to 0.99). RR in the only placebo-controlled PPI trial was 0.35 (95% CI, 0.26 to 0.46). The sRR for standard dose PPIs versus H2RAs was 0.55 (95% CI, 0.44 to 0.68). In treatment of ENRD, both PPis (sRR, 0.64; 95% CI, 0.52 to 0.79) and H2RAs (sRR, 0.78; 95% CI, 0.62 to 0.97) were superior to placebo, and PPis were superior to H2RAs (sRR, 0.81; 95% CI, 0.70 to 0.95).

CONCLUSIONS: Acid suppressant therapy (with a PPI or an H2RA) is more effective than placebo for short-term relief of heartburn in patients with persistent symptoms who are treated empirically for GERD and in those in whom esophagitis was excluded after endoscopy. The benefit of PPIs compared with H2RAs is more pronounced in patients treated empirically.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 1999;94:1434–42.

    Article  PubMed  CAS  Google Scholar 

  2. Corder AP, Jones RH, Sadler GH, Daniels P, Johnson CD. Heartburn, oesophagitis and Barrett’s oesophagus in self-medicating patients in general practice. Br J Clin Pract. 1996;50:245–8.

    PubMed  CAS  Google Scholar 

  3. Isolauri J, Laippala P. Prevalence of symptoms suggestive of gastro-oesophageal reflux disease in an adult population. Ann Med. 1995;27:67–70.

    PubMed  CAS  Google Scholar 

  4. Locke GR, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology. 1997;112:1448–56.

    Article  PubMed  Google Scholar 

  5. Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Dig Dis. 1976;21:953–6.

    Article  PubMed  CAS  Google Scholar 

  6. Thompson WG, Heaton KW. Heartburn and globus in apparently healthy people. Can Med Assoc J. 1982;126:46–8.

    PubMed  CAS  Google Scholar 

  7. Dimenas E, Carlsson G, Glise H, Israelsson B, Wiklund I. Relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease. Scand J Gastroenterol. 1996;221(suppl):8–13.

    CAS  Google Scholar 

  8. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112:1798–810.

    Article  PubMed  CAS  Google Scholar 

  9. Kroes RM, Numans ME, Jones RH, de Wit NJ, Verheij TJM. Gastrooesophageal reflux disease in primary care. Comparison and evaluation of existing national guidelines and development of uniform European guidelines. Eur J Gen Pract. 1999;5:88–97.

    Article  Google Scholar 

  10. Joelsson B, Johnsson F. Heartburn—the acid test. Gut. 1989;30:1523–5.

    PubMed  CAS  Google Scholar 

  11. Johansson KE, Ask P, Boeryd B, Fransson SG, Tibbling L. Oesophagitis, signs of reflux, and gastric acid secretion in patients with symptoms of gastro-oesophageal reflux disease. Scand J Gastroenterol. 1986;21:837–47.

    PubMed  CAS  Google Scholar 

  12. Johnsson F, Joelsson B, Gudmundsson K, Greiff L. Symptoms and endoscopic findings in the diagnosis of gastroesophageal reflux disease. Scand J Gastroenterol. 1987;22:714–8.

    PubMed  CAS  Google Scholar 

  13. Robinson M, Earnest D, Rodriguez-Stanley S, et al. Heartburn requiring frequent antacid use may indicate significant illness. Arch Intern Med. 1998;158:2373–6.

    Article  PubMed  CAS  Google Scholar 

  14. Tefera L, Fein M, Ritter MP, et al. Can the combination of symptoms and endoscopy confirm the presence of gastroesophageal reflux disease? Am Surg. 1997;63:933–6.

    PubMed  CAS  Google Scholar 

  15. Dent J. Gastro-oesophageal reflux disease. Digestion. 1998;59:433–45.

    Article  PubMed  CAS  Google Scholar 

  16. Rodriguez-Stanley S, Robinson M, Earnest DL, Greenwood-Van MB, Miner PB Jr. Esophageal hypersensitivity may be a major cause of heartburn. Am J Gastroenterol. 1999;94:628–31.

    Article  PubMed  CAS  Google Scholar 

  17. Shi G, Bruley des Varannes S, Scarpignato C, Le Rhun M, Galmiche JP. Reflux related symptoms in patients with normal oesophageal exposure to acid. Gut. 1995;37:457–64.

    PubMed  CAS  Google Scholar 

  18. Laird NM, Mosteller F. Some statistical methods for combining experimental results. Int J Technol Assess Health Care. 2003;24:243–6.

    Google Scholar 

  19. Lau J, Ioannidis JPA, Schmid CH. Summing up evidence: one answer is not always enough. Lancet. 1998;351:123–7.

    Article  PubMed  CAS  Google Scholar 

  20. Engels EA, Schmid CH, Terrin N, Olkin I, Lau J. Heterogeneity and statistical significance in meta-analysis: an empirical study of 125 meta-analyses. Stat Med. 2000;19:1707–28.

    Article  PubMed  CAS  Google Scholar 

  21. Deeks JJ. Issues in the selection of summary statistics of meta-analyses of clinical trials with binary outcomes. Stat Med. 2002;21:1575–600.

    Article  PubMed  Google Scholar 

  22. Schindlbeck NE, Klauser AG, Voderholzer WA, Muller-Lissner S. Empiric therapy for gastroesophageal reflux disease. Arch Intern Med. 1995;155:1808–12.

    Article  PubMed  CAS  Google Scholar 

  23. Robinson MG, Orr WC, McCallum R, Nardi R. Do endoscopic findings influence response to H2 antagonist therapy for gastroesophageal reflux disease? Am J Gastroenterol. 1987;82:519–22.

    PubMed  CAS  Google Scholar 

  24. Powell-Jackson P, Barkley H, Northfield TC. Effect of cimetidine in symptomatic gastro-oesophageal reflux. Lancet. 1978;2:1068–9.

    Article  PubMed  CAS  Google Scholar 

  25. Marrero JM, de Caestecker JS, Maxwell JD. Effect of famotidine on oesophageal sensitivity in gastro-oesopahgeal reflux disease. Gut. 1994;35:447–50.

    PubMed  CAS  Google Scholar 

  26. Johnsson F, Weywadt L, Solhaug J-H, Hernqvist H, Bengtsson L. One-week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease. Scand J Gastroenterol. 1998;33:15–20.

    Article  PubMed  CAS  Google Scholar 

  27. Johnsson F, Roth Y, Damgaard Pedersen N-E, Joelsson B. Cimetidine improves GERD symptoms in patients selected by a validated GERD questionnaire. Aliment Pharmacol Ther. 1993;7:81–6.

    Article  PubMed  CAS  Google Scholar 

  28. Jebbink HJA, Smout AJPM, van Berge Henegouwen GP. Ranitidine vooral werkzaam bij functionele dyspepsie met klachten passend bij refluxziekten. Ned Tijdschr Geneeskd. 1993;137:1772–5.

    PubMed  CAS  Google Scholar 

  29. Greaney MG, Irvin TT. Cimetidine for the treatment of symptomatic gastro-oesophageal reflux. Br J Clin Pract. 1981;35:21–4.

    PubMed  CAS  Google Scholar 

  30. Bennett JR, Buckton G, Martin HD. Cimetidine in gastro-oesophageal reflux. Digestion. 1983;26:166–72.

    Article  PubMed  CAS  Google Scholar 

  31. Johansson KE, Boeryd B, Johansson K, Tibbling L. Double-blind crossover study of ranitidine and placebo in gastro-oesophageal reflux disease. Scand J Gastroenterol. 1986;21:769–78.

    PubMed  CAS  Google Scholar 

  32. Richter JE, Campbell DR, Kahrilas PJ, Huang B, Fludas C. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. Arch Intern Med. 2000;160:1803–9.

    Article  PubMed  CAS  Google Scholar 

  33. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, et al. Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol. 1997;92:1997–2000 (see comments).

    PubMed  CAS  Google Scholar 

  34. Behar J, Brand DL, Brown FC, et al. Cimetidine in the treatment of symptomatic gastroesophageal reflux: a double blind controlled trial. Gastroenterology. 1978;74:441–8.

    PubMed  CAS  Google Scholar 

  35. Bright-Asare P, El-Bassoussi M. Cimetidine, metoclopramide, or placebo in the treatment of symptomatic gastroesophageal reflux. J Clin Gastroenterol. 1980;2:149–56.

    Article  PubMed  CAS  Google Scholar 

  36. Fiasse R, Hanin C, Lepot A, Descamps C, Lamy F, Dive C. Controlled trial of cimetidine in reflux esophagitis. Dig Dis Sci. 1980;25:750–5.

    Article  PubMed  CAS  Google Scholar 

  37. Robinson M, Decktor DL, Stone RC, et al. Famotidine (20 mg) b.i.d. relieves gastrooesophageal reflux symptoms in patients without erosive oesophagitis. Famotidine/GERD Investigation Group. Aliment Pharmacol Ther. 1991;5:631–43.

    Article  Google Scholar 

  38. Sabesin SM, Berlin RG, Humphries TJ, Bradstreet DC, Walton-Bowen KL, Zaidi S. Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. Results of a multicenter, placebo-controlled, dose-ranging study. USA Merck Gastroesophageal Reflux Disease Study Group. Arch Intern Med. 1991;151:2394–400.

    Article  PubMed  CAS  Google Scholar 

  39. Sontag S, Robinson M, McCallum RW, Barwick KW, Nardi R. Ranitidine therapy for gastroesophageal reflux disease. Results of a large double-blind trial. Arch Intern Med. 1987;147:1485–91.

    Article  PubMed  CAS  Google Scholar 

  40. Watson RG, Tham TC, Johnston BT, McDougall NI. Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux—the “sensitive oesophagus. Gut. 1997;40:587–90.

    PubMed  CAS  Google Scholar 

  41. Armstrong D, Pare P, Pericak D, Pyzyk M, Canadian Pantoprazole GERD Study Group. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease. Am J Gastroenterol. 2001;96:2849–57.

    PubMed  CAS  Google Scholar 

  42. Bate CM, Green JR, Axon AT, et al. Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis. Aliment Pharmacol Ther. 1997;11:755–63.

    Article  PubMed  CAS  Google Scholar 

  43. Venables TL, Newland RD, Patel AC, Hole J, Wilcock C, Turbitt ML. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol. 1997;32:965–73.

    PubMed  CAS  Google Scholar 

  44. Rush DR, Stelmach WJ, Young TL, et al. Clinical effectiveness and quality of life with ranitidine vs placebo in gastroesophageal reflux disease patients: a clinical experience network (CEN) study. J Fam Pract. 1995;41:126–36 (see comments).

    PubMed  CAS  Google Scholar 

  45. Bardhan KD, Muller-Lissner S, Bigard MA, et al. Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study Group. BMJ. 1999;318:502–7.

    PubMed  CAS  Google Scholar 

  46. Hallerback B, Glise H, Johansson B, et al. Gastro-oesophageal reflux symptoms—clinical findings and effect of ranitidine treatment. Eur J Surg. 1998;583:6–13.

    Article  Google Scholar 

  47. Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol. 1998;10:119–24.

    Article  PubMed  CAS  Google Scholar 

  48. Riemann JF, Hobel W. Cimetidine suspension in patients with stage 0 gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1991;5:191–7.

    Article  PubMed  CAS  Google Scholar 

  49. Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol. 1997;32:974–9.

    Article  PubMed  CAS  Google Scholar 

  50. Havelund T, Lind T, Wiklund I, et al. Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole. Am J Gastroenterol. 1999;94:1782–9.

    Article  PubMed  CAS  Google Scholar 

  51. Hatlebakk JG, Hyggen A, Madsen PH, et al. Heartburn treatment in primary care: randomised, double blind study for 8 weeks. BMJ. 1999;319:550–3.

    PubMed  CAS  Google Scholar 

  52. Bate CM, Griffin SM, Keeling PW, et al. Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis. Aliment Pharmacol Ther. 1996;10:547–55.

    Article  PubMed  CAS  Google Scholar 

  53. Miner PB Jr, Orr W, Filippone J, Jokubaitis L, Sloan S. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol. 2002;97:1332–9.

    Article  PubMed  CAS  Google Scholar 

  54. Richter JE, Peura D, Benjamin SB, Joelsson B, Whipple J. Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis. Arch Intern Med. 2000;160:1810–6.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mattijs E. Numans MD, PhD.

Additional information

This research is part of the GERD-guidelines project that was initiated by the European Society for Primary Care Gastroenterology, was conducted in cooperation with the Upper Gastrointestinal and Pancreatic Diseases Group of the Cochrane Collaboration, and also was supported by a grant of the Agency for Healthcare Research and Quality of the U.S. Public Health Service, R25 HS09796.

Rights and permissions

Reprints and permissions

About this article

Cite this article

van Pinxteren, B., Numans, M.E., Lau, J. et al. Short-term treatment of gastroesophageal reflux disease. J GEN INTERN MED 18, 755–763 (2003). https://doi.org/10.1046/j.1525-1497.2003.20833.x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1046/j.1525-1497.2003.20833.x

Key words

Navigation